Suppr超能文献

组织型纤溶酶原激活物及其丝氨酸蛋白酶抑制剂1型纤溶酶原激活物抑制剂的复合物通过低密度脂蛋白受体相关蛋白/α2-巨球蛋白受体被内化。

Complexes of tissue-type plasminogen activator and its serpin inhibitor plasminogen-activator inhibitor type 1 are internalized by means of the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor.

作者信息

Orth K, Madison E L, Gething M J, Sambrook J F, Herz J

机构信息

Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas 75235.

出版信息

Proc Natl Acad Sci U S A. 1992 Aug 15;89(16):7422-6. doi: 10.1073/pnas.89.16.7422.

Abstract

Tissue-type plasminogen activator and urokinase are serine proteases secreted by many cell types that participate in biological processes, such as tissue restructuring, cell migration, and tumor metastasis. Clinically, these proteases are used to dissolve coronary fibrin clots that are the proximal causes of acute myocardial infarction. In vivo, the activity of these enzymes is controlled by plasminogen-activator inhibitors, members of the serpin family of protease inhibitors. This study shows that tissue-type plasminogen activator-inhibitor complexes bind in solution to low density lipoprotein receptor-related protein (LRP), a large heterodimeric ubiquitous membrane receptor. In cultured cells, endocytosis and degradation of these complexes is reduced by polyclonal antibodies directed against LRP and inhibited by a M(r) 39,000 protein that binds to LRP and inhibits its interaction with previously known ligands, including apolipoprotein E and alpha 2-macroglobulin. We propose a role for LRP in the clearance of plasminogen activator-inhibitor complexes that is analogous to its function in the endocytosis of alpha 2-macroglobulin-protease complexes.

摘要

组织型纤溶酶原激活剂和尿激酶是由多种细胞类型分泌的丝氨酸蛋白酶,它们参与组织重塑、细胞迁移和肿瘤转移等生物学过程。临床上,这些蛋白酶用于溶解作为急性心肌梗死近端病因的冠状动脉纤维蛋白凝块。在体内,这些酶的活性受纤溶酶原激活剂抑制剂控制,后者是丝氨酸蛋白酶抑制剂丝氨酸蛋白酶抑制剂家族的成员。本研究表明,组织型纤溶酶原激活剂-抑制剂复合物在溶液中与低密度脂蛋白受体相关蛋白(LRP)结合,LRP是一种大型异源二聚体普遍存在的膜受体。在培养细胞中,针对LRP的多克隆抗体可减少这些复合物的内吞作用和降解,一种分子量为39000的蛋白质可抑制其与LRP的结合,并抑制其与包括载脂蛋白E和α2-巨球蛋白在内的先前已知配体的相互作用。我们提出LRP在纤溶酶原激活剂-抑制剂复合物清除中的作用类似于其在α2-巨球蛋白-蛋白酶复合物内吞作用中的功能。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb4f/49722/9beb38355d09/pnas01090-0146-a.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验